Dextromethorphan (INN) and its salts
ASEAN Annex II lists this record among substances prohibited in cosmetic products. Member-state transition rules and deviations still require local verification.
규제 판단 및 전체 조건
- 상태
- Prohibited
- 법적 역할
- Binding rule
- 규제 요약
- ASEAN Annex II lists this record among substances prohibited in cosmetic products. Member-state transition rules and deviations still require local verification.
- 조건 및 제한 사항
- A prohibition entry may contain no separate condition text because the regulatory outcome is the prohibition itself. 인용된 출처를 열고 아래의 시장 전체 요건을 적용하세요.
물질 정체
- 공식 출처상의 명칭
- Dextromethorphan (INN) and its salts
- CAS
- 125-71-3
- EC
- Not supplied in this source row
- 정체 매핑
- standalone:official_asean_record
이 정체의 시장 간 요약
현재 이 사이트에 있는 정확히 연결된 기록입니다. 시장이 없는 것은 가져온 정확한 일치 항목이 없다는 뜻이며, 해당 물질의 사용이 허용된다는 뜻이 아닙니다.
European Union
연결된 기록 1건
보조 기록 열기Great Britain
연결된 기록 1건
보조 기록 열기Canada
연결된 기록 1건
보조 기록 열기New Zealand
연결된 기록 1건
보조 기록 열기ASEAN
현재 기록연결된 기록 1건
보조 기록 열기China
연결된 기록 1건 · 특정 조건이 있는 기록 1건
보조 기록 열기South Korea
연결된 기록 1건 · 특정 조건이 있는 기록 1건
보조 기록 열기Brazil
연결된 기록 1건 · 특정 조건이 있는 기록 1건
보조 기록 열기India
연결된 기록 1건 · 특정 조건이 있는 기록 1건
보조 기록 열기Saudi Arabia
연결된 기록 1건
보조 기록 열기
CAS 125-71-3의 검증된 화학 정보
Dextromethorphan
Dextromethorphan is a 6-methoxy-11-methyl-1,3,4,9,10,10a-hexahydro-2H-10,4a-(epiminoethano)phenanthrene in which the sterocenters at positions 4a, 10 and 10a have S-configuration. It is a prodrug of dextrorphan and used as an antitussive drug for suppressing cough. It has a role as a oneirogen, a xenobiotic, a prodrug, a neurotoxin, an antitussive, a NMDA receptor antagonist and an environmental contaminant. It is functionally related to a dextrorphan. It is an enantiomer of a levomethorphan. — ChEBI
- IUPAC 명칭
- (1S,9S,10S)-4-methoxy-17-methyl-17-azatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,5-triene
- 분자식
- C18H25NO
- 분자량
- 271.4 g/mol
- 정확한 질량
- 271.193614421 Da
- 단일 동위원소 질량
- 271.193614421 Da
- XLogP3
- 3.4
- 위상 극성 표면적
- 12.5 Ų
- 분자 복잡도
- 370.0
- 형식 전하
- 0
- 수소 결합 공여체
- 0
- 수소 결합 수용체
- 2
- 회전 가능 결합
- 1
- 중원자
- 20
- 공유결합 단위
- 1
PubChem에 보고된 명칭 및 동의어
보고된 명칭 16개 더 보기
외부 데이터베이스 식별자
- ChEBI:CHEBI:4470
- ChEBI:CHEBI:92579
- ChEMBL:CHEMBL52440
- EPA DTXSID:DTXSID3022908
- PubMed:22608604
- PubMed:22073096
- PubMed:22066053
- PubMed:22044595
- PubMed:21973086
- PubMed:21867562
- PubMed:21614312
- PubMed:21445282
- PubMed:21436715
- PubMed:21266064
- PubMed:21244712
- PubMed:21175434
고급 구조 통계
- 정의된 원자 입체중심
- 3
- 정의되지 않은 원자 입체중심
- 0
- 정의된 결합 입체중심
- 0
- 정의되지 않은 결합 입체중심
- 0
- 3D 파마코포어 특성
- 6
- 3D 고리
- 4
- 3D 소수성 부위
- 0
- 3D 수용체 특성
- 1
- 3D 공여체 특성
- 0
- 3D 음이온 중심
- 0
- 3D 양이온 중심
- 1
- 3D 형태이성질체
- 2
- 유효 3D 회전자
- 2.6
기계 판독 가능한 구조 식별자
- SMILES
CN1CC[C@@]23CCCC[C@@H]2[C@@H]1CC4=C3C=C(C=C4)OC- InChI
InChI=1S/C18H25NO/c1-19-10-9-18-8-4-3-5-15(18)17(19)11-13-6-7-14(20-2)12-16(13)18/h6-7,12,15,17H,3-5,8-11H2,1-2H3/t15-,17+,18+/m1/s1- InChIKey
MKXZASYAUGDDCJ-NJAFHUGGSA-N
추가 과학 데이터베이스의 근거
NIH PubChem PUG-View
Attributed physical-property, hazard, environmental and use annotations.
- Color/Form: White to slightly yellow crystalline powder 출처: Hazardous Substances Data Bank (HSDB)
- Melting Point: 122-124 출처: DrugBank
- Melting Point: 109-111 °C 출처: Hazardous Substances Data Bank (HSDB)
- Odor: Odorless 출처: Hazardous Substances Data Bank (HSDB)
- Solubility: 1.5 g/100 mL 출처: DrugBank
- Solubility: Practically insoluble in water 출처: Hazardous Substances Data Bank (HSDB)
- Solubility: Freely soluble in chloroform 출처: Hazardous Substances Data Bank (HSDB)
- Carcinogen Classification: No indication of carcinogenicity to humans (not listed by IARC). 출처: Toxin and Toxin Target Database (T3DB)
- Exposure Routes: Oral, rapidly absorbed from the gastrointestinal tract. 출처: Toxin and Toxin Target Database (T3DB)
- Note: This chemical does not meet GHS hazard criteria for 46.8% (36 of 77) of reports. 출처: European Chemicals Agency (ECHA)
- Signal: Danger 출처: European Chemicals Agency (ECHA)
- GHS Hazard Statements: H301 (51.9%): Toxic if swallowed [Danger Acute toxicity, oral] 출처: European Chemicals Agency (ECHA)
- Precautionary Statement Codes: P264, P270, P301+P316, P321, P330, P405, and P501 (click each P-code to see the statement) 출처: European Chemicals Agency (ECHA)
- ECHA C&L Notifications Summary: Aggregated GHS information provided per 77 reports by companies from 4 notifications to the ECHA C&L Inventory.; Reported as not meeting GHS hazard criteria per 36 of 77 reports by companies.; There are 3 notifications provided by 41 of 77 reports by companies with hazard statement code(s).; Information may vary between notifications depending on impurities, additives, and other factors. The percentage value in parenthesis indicates the notified classification ratio from companies that provide hazard codes. Only hazard codes with percentage values above 10% are shown. For more detailed information, please visit ECHA C&L website. 출처: European Chemicals Agency (ECHA)
- Health Effects: Hypertension, shallow respiration. Dextromethorphan can cause other gastrointestinal disturbances. [Wikipedia] 출처: Toxin and Toxin Target Database (T3DB)
- Toxicity Summary: IDENTIFICATION AND USE: Dextromethorphan is a white odorless solid crystal or powder. It is an opium alkaloid derivative, which is found in cough and cold preparations. HUMAN STUDIES: Dextromethorphan is a drug of abuse. The main risks associated with dextromethorphan are ataxia, central nervous system (CNS) stimulation, dizziness, lethargy and psychotic behavior. Less frequently with large doses seizures and respiratory depression can occur. Nausea, vomiting, constipation and tachycardia may also occur. CNS effects include ataxia, drowsiness, vertigo and rarely coma. CNS stimulation may be observed. Restlessness, increased muscle tone with body rigidity have been reported. With extremely large ingestions respiratory depression can occur. Gastrointestinal effects include nausea, vomiting, constipation and dry mouth. Urinary retention may be seen. Dextromethorphan abuse has been described and produces euphoria, CNS stimulation, visual and/or auditory hallucinations. Dextromethorphan hydrobromide is the drug form, thus the possibility of bromide poisoning should be considered in the long term abuser. Dextromethorphan enhances serotonin activity by inhibiting the reuptake of serotonin 출처: Hazardous Substances Data Bank (HSDB)
- Toxicity Summary: Signs and Symptoms of Overdose; One significant concern regarding dextromethorphan toxicity is its OTC misuse, which has steadily increased since the early 2000s. This misuse is referred to by slang terms such as "going pharming," "robotripping," and "dexing." In 2006, three specific OTC product formulations accounted for 66% of reported dextromethorphan misuse cases in the United States, with Coricidin HBP Cough & Cold Tablets and Robitussin products being prominent. A life-threatening toxicity associated with dextromethorphan abuse is serotonin syndrome, resulting from its serotonin reuptake inhibition properties. When combined with SSRIs or MAOIs, the risk of serotonin syndrome increases significantly. Symptoms include agitation, confusion, dilated pupils, headache, tachycardia, hypotension, high fever, seizures, irregular heartbeat, and may progress to unconsciousness.; Despite the rise in misuse, public health efforts and legislative actions restricting the sale of dextromethorphan-containing products to minors have helped stabilize or reduce abuse rates in recent years. However, continued vigilance is essential to prevent misuse and associated toxicities, given dextromethorph 출처: StatPearls
- Toxicity Summary: Dextromethorphan is an opioid-like drug that binds to and acts as antagonist to the NMDA glutamatergic receptor, it is an agonist to the opioid sigma 1 and sigma 2 receptors, it is also an alpha3/beta4 nicotinic receptor antagonist and targets the serotonin reuptake pump. Dextromethorphan is rapidly absorbed from the gastrointestinal tract, where it enters the bloodstream and crosses the blood-brain barrier. The first-pass through the hepatic portal vein results in some of the drug being metabolized into an active metabolite of dextromethorphan, dextrorphan, the 3-hydroxy derivative of dextromethorphan. 출처: Toxin and Toxin Target Database (T3DB)
- Environmental Bioconcentration: The estimated pKa of dextromethorphan is 9.8(1), indicating that dextromethorphan will exist almost entirely in the cation form at pH values of 5 to 9 and, therefore, bioconcentration in fish is not expected to be an important fate process(SRC). 출처: Hazardous Substances Data Bank (HSDB)
- Environmental Fate: TERRESTRIAL FATE: Based on a classification scheme(1), an estimated Koc value of 23,000(SRC), determined from a structure estimation method(2), indicates that dextromethorphan is expected to be immobile in soil(SRC). The estimated pKa of dextromethorphan is 9.8(3), indicating that this compound will exist almost entirely in the cation form in the environment and cations generally adsorb more strongly to soils containing organic carbon and clay than their neutral counterparts(4). Volatilization of the cation from moist soil is not expected because cations do not volatilize(SRC). Dextromethorphan is not expected to volatilize from dry soil surfaces(SRC) based upon an estimated vapor pressure of 1.0X10-5 mm Hg at 25 °C(SRC), determined from a fragment constant method(2). Biodegradation data in soil were not available(SRC, 2017). 출처: Hazardous Substances Data Bank (HSDB)
- Environmental Fate: AQUATIC FATE: Based on a classification scheme(1), an estimated Koc value of 23,000(SRC), determined from a structure estimation method(2), indicates that dextromethorphan is expected to adsorb to suspended solids and sediment(SRC). An estimated pKa of 9.8(3) indicates dextromethorphan will exist almost entirely in the cation form at pH values of 5 to 9 and, therefore, volatilization from water surfaces and bioconcentration in aquatic organisms are not expected to be an important fate processes(SRC). Dextromethorphan is not expected to undergo hydrolysis in the environment due to the lack of functional groups that hydrolyze under environmental conditions(4). Biodegradation data in water were not available(SRC, 2017). 출처: Hazardous Substances Data Bank (HSDB)
- Environmental Fate: ATMOSPHERIC FATE: According to a model of gas/particle partitioning of semivolatile organic compounds in the atmosphere(1), dextromethorphan, which has an estimated vapor pressure of 1.0X10-5 mm Hg at 25 °C(SRC), determined from a fragment constant method(2), will exist in both the vapor and particulate phases in the ambient atmosphere. Vapor-phase dextromethorphan is degraded in the atmosphere by reaction with photochemically-produced hydroxyl radicals(SRC); the half-life for this reaction in air is estimated to be 3.3 hours(SRC), calculated from its rate constant of 1.2X10-10 cu cm/molecule-sec at 25 °C(SRC) that was derived using a structure estimation method(2). Particulate-phase dextromethorphan may be removed from the air by wet or dry deposition(SRC). Dextromethorphan contains chromophores that absorb at wavelengths >290 nm(3) and, therefore, is expected to be susceptible to direct photolysis by sunlight(SRC). 출처: Hazardous Substances Data Bank (HSDB)
- Uses: Antitussive Agents; Excitatory Amino Acid Antagonists 출처: Hazardous Substances Data Bank (HSDB)
- Uses: Probe to determine cytochrome 450 phenotype 출처: Hazardous Substances Data Bank (HSDB)
- Uses: MEDICATION 출처: Hazardous Substances Data Bank (HSDB)
- Uses: Dextromethorphan (DXM) is an over-the-counter (OTC) cough suppressant commonly found in cold medications. DXM is often abused in high doses by adolescents to generate euphoria and visual and auditory hallucinations. Illicit use of DXM is referred to on the street as "Robo-tripping" or "skittling." These terms are derived from the most commonly abused products, Robitussin and Coricidin. 출처: Hazardous Substances Data Bank (HSDB)
- Uses: Use (kg; approx.) in Germany (2009): >1000; Use (kg) in USA (2002): 38000; Consumption (g per capita; approx.) in Germany (2009): 0.0122; Consumption (g per capita) in the USA (2002): 0.135; Excretion rate: 0.25; Calculated removal (%): 45.3 출처: NORMAN Suspect List Exchange
- Uses: The primary use of dextromethorphan is as a cough suppressant, for the temporary relief of cough caused by minor throat and bronchial irritation (as commonly accompanies the common cold), as well as those resulting from inhaled irritants. In addition, a combination of dextromethorphan and quinidine has been shown to alleviate symptoms of easy laughing and crying (pseudobulbar affect) in patients with amyotrophic lateral sclerosis and multiple sclerosis. 출처: Toxin and Toxin Target Database (T3DB)
매핑 기준: Existing checksum-valid CAS to unique PubChem CID match. 가져온 시각: 2026-08-31. 출처 기록 열기
과학적 분류와 유해성 주석은 맥락을 제공할 뿐이며, 위에 표시된 시장별 규제 판단을 대체하지 않습니다.
추가 출처 적용 범위 및 일치 상태
| 출처 | 결과 | 확인됨 |
|---|---|---|
| NIH PubChem PUG-View | 정확히 일치 | 2026-08-31 |
기록된 불일치는 출처를 확인했다는 유용한 근거이며, 해당 물질이 다른 곳에 존재하지 않는다는 주장이 아닙니다.
체크섬이 유효한 CAS 일치를 통해 2026-08-31에 NIH PubChem에서 가져왔습니다. 화학적 특성은 이 페이지의 규제 판단을 대체하지 않습니다.
공식 출처 및 출처 정보
- 등록된 출처
- ASEAN Cosmetic Directive annexes
- 출처 참조
- ASEAN Annex II, reference 226
- 출처 기록 ID
II-226- 출처 버전
- 2026-1
- 출처 언어
- English
- 번역 상태
- Original is English
- 출처 업데이트
- 2026-06-22
- 스냅샷 확인
- 2026-08-30 04:44 UTC
- 검증 방법
- pdfplumber ruled-table extraction with per-annex reviewed counts
- SHA-256
ffad59f6c01a92c82042c54203ee14969425c2a82bd04c2f4012ff82513e69f1
등록된 데이터세트 주석
- 데이터세트 적용 범위
- Banned, restricted and positive-list substances under the harmonised ASEAN framework
- 권위 관련 주석
- Regional directive; member-state transitions and deviations still require local verification
이 기록이 시장 데이터세트에서 차지하는 위치
상태 분포
현재 기록 2224건 중 462건에 조건 텍스트가 있습니다. 조건 필드가 비어 있는 경우 위의 기록 유형에 따라 해석되며, 제한 없는 사용에 대한 주장으로 전환되지 않습니다.
ASEAN 시장 맥락
Complete regional annex dataset
적용 범위 버전: ASEAN Cosmetic Directive annexes 2026-1, 22 June 2026
Annexes II, III, IV, VI and VII covering prohibited, restricted and positive-list substances.
확인 체크리스트
- Search all ACD annexes by name and identifiers.
- Apply product type, maximum level and warning conditions.
- Confirm the target member state's adoption and transition date.
- Complete the local notification and responsible-company requirements.
공식 시장 출처
- ASEAN Cosmetic Directive annexesRegional directive; member-state transitions and deviations still require local verification
확인 절차 및 기록 완전성
이 결과를 규제 준수 판단에 사용하기 전에
- “Dextromethorphan (INN) and its salts”와(과) 모든 CAS/EC 식별자가 공급업체 규격서의 물질을 가리키는지 확인하세요.
- Search all ACD annexes by name and identifiers.
- Apply product type, maximum level and warning conditions.
- Confirm the target member state's adoption and transition date.
- Complete the local notification and responsible-company requirements.
- 출처 버전을 기록하고, 제조, 신고 또는 시장 출시 전에 규제 기관을 다시 확인하세요.
이 기록에서 제공되는 필드
- 공식 물질 명칭제공됨
- CAS제공됨
- EC제공되지 않음
- 별도의 조건 텍스트출처 행에 없음
- 시행일제공되지 않음
- 스냅샷 해시 및 방법제공됨
이 페이지가 답하는 질문
안정적인 인용
Dextromethorphan (INN) and its salts. ASEAN Annex II, reference 226. ASEAN. Source version 2026-1. CosIng Checker regulatory record: https://cosingchecker.com/ko/regulations/asean/records/2368/
법적 권위로서 규제 기관을 인용하세요. 이 페이지는 구조화된 근거 색인이자 확인 보조 도구이며, 공식 본문이나 전문적인 법률 평가를 대체하지 않습니다.
ASEAN의 해석 및 한계
This official record identifies the substance as prohibited for cosmetic use in the stated market scope.
Do not rely on a formulation containing this identity until the cited source, effective date and exact substance match have been verified.
법적 역할 해석 방법
The cited row forms part of a binding rule or legally incorporated list for this market.
이 페이지의 근거
- 기록된 결과: Prohibited
- 법적 역할: Binding rule
- 출처 버전: 2026-1
증명하지 않는 것
Regional annex coverage does not replace member-state implementation dates, notifications or national deviations.
추가 공신력 있는 물질 조사
이 출처들 중 어느 것도 위의 시장 판단을 번복하지 않습니다.
Cosmetic Ingredient Review safety assessments
Expert Panel conclusions, assessed ingredient groups, use conditions, dates and report documents
Independent expert review considered by FDA; not a government approval or binding market rule
출처에서 이 정체 조사FDA Global Substance Registration System
UNII identifiers, preferred names, substance types, codes and public substance relationships
Identity registry only; UNII availability does not imply FDA review or approval
출처에서 이 정체 조사ILO/WHO International Chemical Safety Cards
Hazards, symptoms, first aid, storage, incompatibilities and physical properties for covered chemicals
International occupational chemical-safety reference; not cosmetic-use approval
출처에서 이 정체 조사Japan NITE-CHRIP
Chemical identity, Japanese and foreign legal lists, GHS hazards and exposure-related information
Chemical-management evidence; cosmetic status remains governed by the applicable MHLW standard and market rules
출처에서 이 정체 조사NIOSH Pocket Guide to Chemical Hazards
REL, PEL, IDLH, properties, exposure routes, symptoms, target organs, first aid and measurement methods for covered workplace chemicals
US occupational-health guidance and limits; not a cosmetic ingredient decision
출처에서 이 정체 조사OECD eChemPortal
Gateway to authority-owned physical-property, fate, ecotoxicity, toxicity, exposure and GHS records
Discovery gateway; each linked authority remains responsible for its data
출처에서 이 정체 조사US EPA CompTox CTX APIs
가져오기에 API 키 필요DTXSID identity, experimental and predicted properties, toxicity, bioactivity, exposure and environmental data
Scientific and computational evidence; predictions must remain labelled and do not determine cosmetic legality
출처에서 이 정체 조사